The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.

New York, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Rheumatoid Arthritis Therapeutics Industry" - https://www.reportlinker.com/p06345577/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Rheumatoid Arthritis Therapeutics Market to Reach $66.7 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Rheumatoid Arthritis Therapeutics estimated at US$48.3 Billion in the year 2022, is projected to reach a revised size of US$66.7 Billion by 2030, growing at aCAGR of 4.1% over the period 2022-2030. Pharmaceuticals, one of the segments analyzed in the report, is projected to record 4% CAGR and reach US$28 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Biopharmaceuticals segment is readjusted to a revised 4.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $13.2 Billion, While China is Forecast to Grow at 6.9% CAGR

The Rheumatoid Arthritis Therapeutics market in the U.S. is estimated at US$13.2 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$13.8 Billion by the year 2030 trailing a CAGR of 6.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.2% and 3.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Select Competitors (Total 23 Featured)
- AbbVie, Inc.
- Amgen, Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG
- Johnson & Johnson
- Novartis International AG
- Pfizer, Inc.
- Regeneron Pharmaceuticals, Inc.
- UCB SA


Read the full report: https://www.reportlinker.com/p06345577/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Rheumatoid Arthritis Therapeutics - Global Key Competitors
Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR

Table 2: World Historic Review for Rheumatoid Arthritis
Therapeutics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR

Table 3: World 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2014, 2023 & 2030

Table 4: World Recent Past, Current & Future Analysis for
Pharmaceuticals by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 5: World Historic Review for Pharmaceuticals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 6: World 16-Year Perspective for Pharmaceuticals by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 7: World Recent Past, Current & Future Analysis for
Biopharmaceuticals by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 8: World Historic Review for Biopharmaceuticals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 9: World 16-Year Perspective for Biopharmaceuticals by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 10: World Recent Past, Current & Future Analysis for
Prescription by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 11: World Historic Review for Prescription by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 12: World 16-Year Perspective for Prescription by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 13: World Recent Past, Current & Future Analysis for
Over-the-Counter (OTC) by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 14: World Historic Review for Over-the-Counter (OTC) by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 15: World 16-Year Perspective for Over-the-Counter (OTC)
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 16: World Rheumatoid Arthritis Therapeutics Market
Analysis of Annual Sales in US$ Million for Years 2014 through
2030

III. MARKET ANALYSIS

UNITED STATES
Rheumatoid Arthritis Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United States
for 2023 (E)
Table 17: USA Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Molecule Type -
Pharmaceuticals and Biopharmaceuticals - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 18: USA Historic Review for Rheumatoid Arthritis
Therapeutics by Molecule Type - Pharmaceuticals and
Biopharmaceuticals Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 19: USA 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Molecule Type - Percentage Breakdown of Value
Sales for Pharmaceuticals and Biopharmaceuticals for the Years
2014, 2023 & 2030

Table 20: USA Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Sales Channel -
Prescription and Over-the-Counter (OTC) - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 21: USA Historic Review for Rheumatoid Arthritis
Therapeutics by Sales Channel - Prescription and
Over-the-Counter (OTC) Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 22: USA 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Sales Channel - Percentage Breakdown of Value
Sales for Prescription and Over-the-Counter (OTC) for the Years
2014, 2023 & 2030

CANADA
Table 23: Canada Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Molecule Type -
Pharmaceuticals and Biopharmaceuticals - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 24: Canada Historic Review for Rheumatoid Arthritis
Therapeutics by Molecule Type - Pharmaceuticals and
Biopharmaceuticals Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 25: Canada 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Molecule Type - Percentage Breakdown of Value
Sales for Pharmaceuticals and Biopharmaceuticals for the Years
2014, 2023 & 2030

Table 26: Canada Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Sales Channel -
Prescription and Over-the-Counter (OTC) - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 27: Canada Historic Review for Rheumatoid Arthritis
Therapeutics by Sales Channel - Prescription and
Over-the-Counter (OTC) Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 28: Canada 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Sales Channel - Percentage Breakdown of Value
Sales for Prescription and Over-the-Counter (OTC) for the Years
2014, 2023 & 2030

JAPAN
Rheumatoid Arthritis Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
Table 29: Japan Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Molecule Type -
Pharmaceuticals and Biopharmaceuticals - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 30: Japan Historic Review for Rheumatoid Arthritis
Therapeutics by Molecule Type - Pharmaceuticals and
Biopharmaceuticals Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 31: Japan 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Molecule Type - Percentage Breakdown of Value
Sales for Pharmaceuticals and Biopharmaceuticals for the Years
2014, 2023 & 2030

Table 32: Japan Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Sales Channel -
Prescription and Over-the-Counter (OTC) - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 33: Japan Historic Review for Rheumatoid Arthritis
Therapeutics by Sales Channel - Prescription and
Over-the-Counter (OTC) Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 34: Japan 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Sales Channel - Percentage Breakdown of Value
Sales for Prescription and Over-the-Counter (OTC) for the Years
2014, 2023 & 2030

CHINA
Rheumatoid Arthritis Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in China for 2023 (E)
Table 35: China Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Molecule Type -
Pharmaceuticals and Biopharmaceuticals - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 36: China Historic Review for Rheumatoid Arthritis
Therapeutics by Molecule Type - Pharmaceuticals and
Biopharmaceuticals Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 37: China 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Molecule Type - Percentage Breakdown of Value
Sales for Pharmaceuticals and Biopharmaceuticals for the Years
2014, 2023 & 2030

Table 38: China Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Sales Channel -
Prescription and Over-the-Counter (OTC) - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 39: China Historic Review for Rheumatoid Arthritis
Therapeutics by Sales Channel - Prescription and
Over-the-Counter (OTC) Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 40: China 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Sales Channel - Percentage Breakdown of Value
Sales for Prescription and Over-the-Counter (OTC) for the Years
2014, 2023 & 2030

EUROPE
Rheumatoid Arthritis Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
Table 41: Europe Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Geographic Region -
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 42: Europe Historic Review for Rheumatoid Arthritis
Therapeutics by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 43: Europe 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for France, Germany, Italy, UK, Spain, Russia and
Rest of Europe Markets for Years 2014, 2023 & 2030

Table 44: Europe Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Molecule Type -
Pharmaceuticals and Biopharmaceuticals - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 45: Europe Historic Review for Rheumatoid Arthritis
Therapeutics by Molecule Type - Pharmaceuticals and
Biopharmaceuticals Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 46: Europe 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Molecule Type - Percentage Breakdown of Value
Sales for Pharmaceuticals and Biopharmaceuticals for the Years
2014, 2023 & 2030

Table 47: Europe Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Sales Channel -
Prescription and Over-the-Counter (OTC) - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 48: Europe Historic Review for Rheumatoid Arthritis
Therapeutics by Sales Channel - Prescription and
Over-the-Counter (OTC) Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 49: Europe 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Sales Channel - Percentage Breakdown of Value
Sales for Prescription and Over-the-Counter (OTC) for the Years
2014, 2023 & 2030

FRANCE
Rheumatoid Arthritis Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in France for 2023 (E)
Table 50: France Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Molecule Type -
Pharmaceuticals and Biopharmaceuticals - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 51: France Historic Review for Rheumatoid Arthritis
Therapeutics by Molecule Type - Pharmaceuticals and
Biopharmaceuticals Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 52: France 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Molecule Type - Percentage Breakdown of Value
Sales for Pharmaceuticals and Biopharmaceuticals for the Years
2014, 2023 & 2030

Table 53: France Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Sales Channel -
Prescription and Over-the-Counter (OTC) - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 54: France Historic Review for Rheumatoid Arthritis
Therapeutics by Sales Channel - Prescription and
Over-the-Counter (OTC) Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 55: France 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Sales Channel - Percentage Breakdown of Value
Sales for Prescription and Over-the-Counter (OTC) for the Years
2014, 2023 & 2030

GERMANY
Rheumatoid Arthritis Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
Table 56: Germany Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Molecule Type -
Pharmaceuticals and Biopharmaceuticals - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 57: Germany Historic Review for Rheumatoid Arthritis
Therapeutics by Molecule Type - Pharmaceuticals and
Biopharmaceuticals Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 58: Germany 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Molecule Type - Percentage Breakdown of Value
Sales for Pharmaceuticals and Biopharmaceuticals for the Years
2014, 2023 & 2030

Table 59: Germany Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Sales Channel -
Prescription and Over-the-Counter (OTC) - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 60: Germany Historic Review for Rheumatoid Arthritis
Therapeutics by Sales Channel - Prescription and
Over-the-Counter (OTC) Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 61: Germany 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Sales Channel - Percentage Breakdown of Value
Sales for Prescription and Over-the-Counter (OTC) for the Years
2014, 2023 & 2030

ITALY
Table 62: Italy Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Molecule Type -
Pharmaceuticals and Biopharmaceuticals - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 63: Italy Historic Review for Rheumatoid Arthritis
Therapeutics by Molecule Type - Pharmaceuticals and
Biopharmaceuticals Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 64: Italy 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Molecule Type - Percentage Breakdown of Value
Sales for Pharmaceuticals and Biopharmaceuticals for the Years
2014, 2023 & 2030

Table 65: Italy Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Sales Channel -
Prescription and Over-the-Counter (OTC) - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 66: Italy Historic Review for Rheumatoid Arthritis
Therapeutics by Sales Channel - Prescription and
Over-the-Counter (OTC) Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 67: Italy 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Sales Channel - Percentage Breakdown of Value
Sales for Prescription and Over-the-Counter (OTC) for the Years
2014, 2023 & 2030

UNITED KINGDOM
Rheumatoid Arthritis Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United Kingdom
for 2023 (E)
Table 68: UK Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Molecule Type -
Pharmaceuticals and Biopharmaceuticals - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 69: UK Historic Review for Rheumatoid Arthritis
Therapeutics by Molecule Type - Pharmaceuticals and
Biopharmaceuticals Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 70: UK 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Molecule Type - Percentage Breakdown of Value
Sales for Pharmaceuticals and Biopharmaceuticals for the Years
2014, 2023 & 2030

Table 71: UK Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Sales Channel -
Prescription and Over-the-Counter (OTC) - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 72: UK Historic Review for Rheumatoid Arthritis
Therapeutics by Sales Channel - Prescription and
Over-the-Counter (OTC) Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 73: UK 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Sales Channel - Percentage Breakdown of Value
Sales for Prescription and Over-the-Counter (OTC) for the Years
2014, 2023 & 2030

SPAIN
Table 74: Spain Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Molecule Type -
Pharmaceuticals and Biopharmaceuticals - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 75: Spain Historic Review for Rheumatoid Arthritis
Therapeutics by Molecule Type - Pharmaceuticals and
Biopharmaceuticals Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 76: Spain 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Molecule Type - Percentage Breakdown of Value
Sales for Pharmaceuticals and Biopharmaceuticals for the Years
2014, 2023 & 2030

Table 77: Spain Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Sales Channel -
Prescription and Over-the-Counter (OTC) - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 78: Spain Historic Review for Rheumatoid Arthritis
Therapeutics by Sales Channel - Prescription and
Over-the-Counter (OTC) Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 79: Spain 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Sales Channel - Percentage Breakdown of Value
Sales for Prescription and Over-the-Counter (OTC) for the Years
2014, 2023 & 2030

RUSSIA
Table 80: Russia Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Molecule Type -
Pharmaceuticals and Biopharmaceuticals - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 81: Russia Historic Review for Rheumatoid Arthritis
Therapeutics by Molecule Type - Pharmaceuticals and
Biopharmaceuticals Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 82: Russia 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Molecule Type - Percentage Breakdown of Value
Sales for Pharmaceuticals and Biopharmaceuticals for the Years
2014, 2023 & 2030

Table 83: Russia Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Sales Channel -
Prescription and Over-the-Counter (OTC) - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 84: Russia Historic Review for Rheumatoid Arthritis
Therapeutics by Sales Channel - Prescription and
Over-the-Counter (OTC) Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 85: Russia 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Sales Channel - Percentage Breakdown of Value
Sales for Prescription and Over-the-Counter (OTC) for the Years
2014, 2023 & 2030

REST OF EUROPE
Table 86: Rest of Europe Recent Past, Current & Future Analysis
for Rheumatoid Arthritis Therapeutics by Molecule Type -
Pharmaceuticals and Biopharmaceuticals - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 87: Rest of Europe Historic Review for Rheumatoid
Arthritis Therapeutics by Molecule Type - Pharmaceuticals and
Biopharmaceuticals Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 88: Rest of Europe 16-Year Perspective for Rheumatoid
Arthritis Therapeutics by Molecule Type - Percentage Breakdown
of Value Sales for Pharmaceuticals and Biopharmaceuticals for
the Years 2014, 2023 & 2030

Table 89: Rest of Europe Recent Past, Current & Future Analysis
for Rheumatoid Arthritis Therapeutics by Sales Channel -
Prescription and Over-the-Counter (OTC) - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 90: Rest of Europe Historic Review for Rheumatoid
Arthritis Therapeutics by Sales Channel - Prescription and
Over-the-Counter (OTC) Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 91: Rest of Europe 16-Year Perspective for Rheumatoid
Arthritis Therapeutics by Sales Channel - Percentage Breakdown
of Value Sales for Prescription and Over-the-Counter (OTC) for
the Years 2014, 2023 & 2030

ASIA-PACIFIC
Rheumatoid Arthritis Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Asia-Pacific for
2023 (E)
Table 92: Asia-Pacific Recent Past, Current & Future Analysis
for Rheumatoid Arthritis Therapeutics by Geographic Region -
Australia, India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 93: Asia-Pacific Historic Review for Rheumatoid Arthritis
Therapeutics by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 94: Asia-Pacific 16-Year Perspective for Rheumatoid
Arthritis Therapeutics by Geographic Region - Percentage
Breakdown of Value Sales for Australia, India, South Korea and
Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030

Table 95: Asia-Pacific Recent Past, Current & Future Analysis
for Rheumatoid Arthritis Therapeutics by Molecule Type -
Pharmaceuticals and Biopharmaceuticals - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 96: Asia-Pacific Historic Review for Rheumatoid Arthritis
Therapeutics by Molecule Type - Pharmaceuticals and
Biopharmaceuticals Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 97: Asia-Pacific 16-Year Perspective for Rheumatoid
Arthritis Therapeutics by Molecule Type - Percentage Breakdown
of Value Sales for Pharmaceuticals and Biopharmaceuticals for
the Years 2014, 2023 & 2030

Table 98: Asia-Pacific Recent Past, Current & Future Analysis
for Rheumatoid Arthritis Therapeutics by Sales Channel -
Prescription and Over-the-Counter (OTC) - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 99: Asia-Pacific Historic Review for Rheumatoid Arthritis
Therapeutics by Sales Channel - Prescription and
Over-the-Counter (OTC) Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 100: Asia-Pacific 16-Year Perspective for Rheumatoid
Arthritis Therapeutics by Sales Channel - Percentage Breakdown
of Value Sales for Prescription and Over-the-Counter (OTC) for
the Years 2014, 2023 & 2030

AUSTRALIA
Rheumatoid Arthritis Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Australia for 2023
(E)
Table 101: Australia Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Molecule Type -
Pharmaceuticals and Biopharmaceuticals - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 102: Australia Historic Review for Rheumatoid Arthritis
Therapeutics by Molecule Type - Pharmaceuticals and
Biopharmaceuticals Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 103: Australia 16-Year Perspective for Rheumatoid
Arthritis Therapeutics by Molecule Type - Percentage Breakdown
of Value Sales for Pharmaceuticals and Biopharmaceuticals for
the Years 2014, 2023 & 2030

Table 104: Australia Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Sales Channel -
Prescription and Over-the-Counter (OTC) - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 105: Australia Historic Review for Rheumatoid Arthritis
Therapeutics by Sales Channel - Prescription and
Over-the-Counter (OTC) Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 106: Australia 16-Year Perspective for Rheumatoid
Arthritis Therapeutics by Sales Channel - Percentage Breakdown
of Value Sales for Prescription and Over-the-Counter (OTC) for
the Years 2014, 2023 & 2030

INDIA
Rheumatoid Arthritis Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in India for 2023 (E)
Table 107: India Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Molecule Type -
Pharmaceuticals and Biopharmaceuticals - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 108: India Historic Review for Rheumatoid Arthritis
Therapeutics by Molecule Type - Pharmaceuticals and
Biopharmaceuticals Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 109: India 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Molecule Type - Percentage Breakdown of Value
Sales for Pharmaceuticals and Biopharmaceuticals for the Years
2014, 2023 & 2030

Table 110: India Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Sales Channel -
Prescription and Over-the-Counter (OTC) - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 111: India Historic Review for Rheumatoid Arthritis
Therapeutics by Sales Channel - Prescription and
Over-the-Counter (OTC) Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 112: India 16-Year Perspective for Rheumatoid Arthritis
Therapeutics by Sales Channel - Percentage Breakdown of Value
Sales for Prescription and Over-the-Counter (OTC) for the Years
2014, 2023 & 2030

SOUTH KOREA
Table 113: South Korea Recent Past, Current & Future Analysis
for Rheumatoid Arthritis Therapeutics by Molecule Type -
Pharmaceuticals and Biopharmaceuticals - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 114: South Korea Historic Review for Rheumatoid Arthritis
Therapeutics by Molecule Type - Pharmaceuticals and
Biopharmaceuticals Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 115: South Korea 16-Year Perspective for Rheumatoid
Arthritis Therapeutics by Molecule Type - Percentage Breakdown
of Value Sales for Pharmaceuticals and Biopharmaceuticals for
the Years 2014, 2023 & 2030

Table 116: South Korea Recent Past, Current & Future Analysis
for Rheumatoid Arthritis Therapeutics by Sales Channel -
Prescription and Over-the-Counter (OTC) - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 117: South Korea Historic Review for Rheumatoid Arthritis
Therapeutics by Sales Channel - Prescription and
Over-the-Counter (OTC) Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 118: South Korea 16-Year Perspective for Rheumatoid
Arthritis Therapeutics by Sales Channel - Percentage Breakdown
of Value Sales for Prescription and Over-the-Counter (OTC) for
the Years 2014, 2023 & 2030

REST OF ASIA-PACIFIC
Table 119: Rest of Asia-Pacific Recent Past, Current & Future
Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type -
Pharmaceuticals and Biopharmaceuticals - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 120: Rest of Asia-Pacific Historic Review for Rheumatoid
Arthritis Therapeutics by Molecule Type - Pharmaceuticals and
Biopharmaceuticals Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 121: Rest of Asia-Pacific 16-Year Perspective for
Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage
Breakdown of Value Sales for Pharmaceuticals and
Biopharmaceuticals for the Years 2014, 2023 & 2030

Table 122: Rest of Asia-Pacific Recent Past, Current & Future
Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel -
Prescription and Over-the-Counter (OTC) - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 123: Rest of Asia-Pacific Historic Review for Rheumatoid
Arthritis Therapeutics by Sales Channel - Prescription and
Over-the-Counter (OTC) Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 124: Rest of Asia-Pacific 16-Year Perspective for
Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage
Breakdown of Value Sales for Prescription and Over-the-Counter
(OTC) for the Years 2014, 2023 & 2030

LATIN AMERICA
Rheumatoid Arthritis Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Latin America for
2023 (E)
Table 125: Latin America Recent Past, Current & Future Analysis
for Rheumatoid Arthritis Therapeutics by Geographic Region -
Argentina, Brazil, Mexico and Rest of Latin America Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06345577/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001